SUMMARY. Concentrations of serum and plasma von Willebrand factor antigen were measured in over 200 patients with a variety of connective tissue diseases, and in control samples from over 200 asymptomatic individuals. This comprehensive study found the highest concentrations of von Wille brand factor antigen in patients with vasculitis, Sjogren's syndrome, Felty's syndrome, giant cell arteritis and polyarteritis nodosum. Raised values were also found in rheumatoid arthritis, systemic lupus erythematosus, polymyalgia rheumatica, systemic sclerosis, Raynaud's syndrome, Takayasu's arteritis and Wegener's granulomatosis, but not in oesteoarthritis. It is possible that the difference in von Wille brand factor antigen concentrations in two sub-groups of systemic necrotising arteritis (Wegener's granulomatosis and polyarteritis nodosum) may imply different disease processes. The large numbers involved have allowed us to confirm or question smaller studies of the role of this molecule in connective tissue disease.
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Vasculitis may arise in the absence of, or in association with other connective tissue diseases such as arthritis. Definitive diagnosis of subgroups of vasculitis can be difficult and may require histological confirmation by biopsy. Since there are no reliable clinical or laboratory indices that provide quantitative assessment of vascular damage, reports of increased concentrations of von Willebrand factor antigen (vWFAg, a specific endothelial cell product) in systemic sclerosis (SSe) and Raynauds syndrome, 1 diabetes-:' and arteritis' fuelled numerous studies into the use of this molecule as aid in diagnosis and disease staging.v" Clinical, in vitro, and animal studies support the concept that increased levels of vWFAg reflect endothelial cell damage or injury-? and not release from platelets or rnegakaryocytes where it is also found as a constituent of alpha granules.l'"!' Previous studies of vWF Ag in connective tissue diseases have sometimes provided conflicting results, possibly as a result of small study numbers and variation in reference values.l,4~8.13~16 With access to a large number and variety of patients with connective tissue disease, we set out to investigate and clarify the value of vWFAg measurement in serum and plasma by ELISA, and to undertake a detailed analysis of vWFAg concentrations in the different sub-types of vasculitis.
PATIENTS AND METHODS
Patients were outpatients attending Rheumatology clinics and inpatients at the Queen Elizabeth and Selly Oak Hospitals, Birmingham, UK. They were classified into disease groups by conventional criteria such as those of American Rheumatism Association. For studies on plasma vWFAg concentrations in vasculitis, patients included two with Churg-Strauss vasculitis, 12 with rheumatoid vasculitis (RV), and one each with cutaneous vasculitis and lupus vasculitis. Similarly, serum vWFAg concentrations in vasculitis were studied in 21 patients with RV, three with polyarteritis nodosum (PAN), two with Takayasu's arteritis, and one each with Wegener's granulomatosis, Schonleiri-Henoch disease, giant cell arteritis (GCA), undifferentiated connective tissue disease and Churg-Strauss vasculitis. Patients were on a variety of therapies such as paracetarnol and nonsteroidal anti-inflammatory drugs, but were not taking cytotoxic agents such as prednisolone or cyclophosphamide. Healthy age and sex matched controls not on any medication were obtained from hospital and laboratory staff. Serum or EDTA-anticoagulated plasma was separated in the laboratory within 2 h of atraumatic venepuncture by centrifugation at 2000 rpm (500 g) and frozen at -20°C until assayed.
vWFAg was assayed by ELISA using commercial antisera.'! Dynatech flat bottomed 96 well microtitre plates were coated with 100 ILL rabbit anti-VWF (Dako, High Wycombe, UK) diluted 1/500 in 0·05 mollL carbonate buffer (pH 9·6) at room temperature (RT) for 60 min. After washing in 250 ILL of phosphate buffered saline (Pbs) plus 0'05070 Tween 20 (Sigma), 100 ILL of serum or standard (National Institute for Biological Standards and Control 3rd British Standard for Blood Factors) diluted 1120, 1/40 and 1180 in pbs/Tween were added to the microtitre plate in duplicate and incubated at RT for 1 h.
Following three washes in pbs/Tween, 100 ILL of rabbit anti-VWF peroxidase conjugate (Dako) diluted 1/500 in pbs/Tween was added to each well and incubated at RT for 45 min. Finally, plates were washed three times in 250 ILL pbsl Tween with one additional wash in a citrate phosphate buffer (pH 5) before the addition of 100ILL of substrate. The substrate was O'5 mg/mL ortho-phenylene diamine hydrochloride (Sigma) diluted in the citrate buffer, supplemented with 0'5mg/mL (lOILL) of 20 volume hydrogen peroxide. The reaction was terminated with the addition of 100 ILL of 2· 5% sulphuric acid to all wells, and the plates were read in an ELISA reader (Titretek Multiskan) at 492 ron. vWFAg concentrations were calculated by comparison of the optical density at each dilution with that of the standard on logarithmic/linear graph paper and reported in IU/dL.
Although values from normal individuals showed a normal, non-skewed distribution, in several cases data on patients groups were skewed. Hence results were analysed by the Mann-Whitney U test. Wilcoxon's Signed Rank Sum test was used for paired data. Calculations were performed on a Minitab statistics package.
RESULTS

Reproducibility
The intra-plate coefficient of variation (CV) was 3·9%. Interplate CVs were estimated at four different concentrations of plasma vWFAg, 11 times each. At a normal vWFAg (98 IU/dL), the CV was 4'0%. At 128 IU/dL it was also 4·0070, but at a high level (219 IU/dL, from a patient with active rheumatoid arthritis) it increased slightly to 4'7%. However, at a very high level (727 IU/dL, from a patient with active vasculitis) that required further dilution, the CV was 9· 3%. Inter-run (day to day) CV was 4·7%.
Serum vs plasma vWF Ag concentrations were consistently lower in serum than in plasma. In paired samples from 73 normal controls, the median serum vWFAg value was 85 IU/dL (range 23-147); in plasma it was 105IU/dL (range 27-183; P<0·05, Wilcoxon Pairs test). In paired samples from 81 patients, the median serum value was 132IU/dL (range 92-2(0); in plasma it was 140 IU/dL (range 100-224, difference not significant).
Normal range
The normal range was derived from values from normal controls. Serum concentrations (n = 281) had a mean of 88 with a standard deviation (SD) of 34 so that the normal range was 20 to 156 IU1dL. Similarly, in plasma (n = 235), the mean value was 104 (SD 43), normal range 18 to 1901U/dL. vWFAg in serum Results from 282 patients with various connective tissue diseases are shown in Table 1 . With the exception of serum from patients with osteoarthritis, all groups had high concentrations of vWFAg. The highest values were found in patients with Sjogren's syndrome, followed by those with vasculitis. The smaller numbers of sub-types of vasculitis, for example, giant cell arteritis, did not allow independent analysis. Levels in SSe were higher than those in Raynaud's syndrome (P<0·05). Lowest concentrations were found in RA, systemic lupus erythematosus (SLE) and Raynaud's syndrome, and values in osteoarthritis were not significantly higher than those of the normal controls.
vWF Ag in plasma Table 2 shows vWFAg concentrations in plasma from 220 patients. The highest vWFAg levels were Generally, the median concentration in each group of patients reflected the proportion of those patients whose vWFAg was above the top of the normal range. No further comparisons between vWFAg concentrations in serum or plasma in the group of patients can be made because of the differences between the patients in each group. Analysis of data according to drug therapy or disease duration or history failed to detect any differences in vWFAg concentrations. Rheumatoid vasculitis was the largest single sub-group within vasculitis. vWFAg concentrations of the group as a whole were not changed by excluding this or any other of the sub-groups.
DISCUSSION
This study confirms and extends similar smaller investigations into the role of vWFAg as a laboratory index in inflammatory vascular disease. However, we have failed to agree with some of the findings of other groups, a partial synopsis of which is shown in Table 3 . Methods used were ELISA,4 as in this study, and Laurell electroirnmunoassay.V A comparison of the two methods found a good correlation (r=O'81, P<O'OOI),u The ELISA method used in this current study probably measures both free vWF and vWF in non-covalent association with factor VIII. However, where raised concentrations do occur at least some vWF Ag may be free and not complexed to factor VIII.s Furthermore, vWFAg is found in plasma at concentrations that are much higher (5) (6) (7) (8) (9) (10) JLg/mL) than those of factor VIII (O'2JLg/mL)Y All previous workers found raised concentrations ofvWFAg in vasculitis and SLE. However, discrepancies arose in studies of patients with RA, SSc and Raynaud's syndrome. In the latter two diseases, results from Woolf's group" are at variance with ours, and this cannot simply be explained by small numbers. The finding of increased concentrations in SSc relative to Raynaud's syndrome may be indicative of a disease process since SSc often develops from Raynaud's syndrome. ' We found a raised serum vWFAg in 55070 of patients with SSc, in 39% with SLE and in 25% with Raynaud's disease, figures very similar to those found by James et al. (62%,38% and 17%, respectively)." In RA, two groupsv" We confirm the findings of a raised level of vWF Ag in Felty's syndrome and normal levels in osteoarthritis." However, Olsson et al." found higher levels in persons with osteoarthrosis of the hips relative to that in healthy young persons. They also recorded slightly higher levels in serum than in plasma, but failed to disclose the nature of the anticoagulant. If 3· 8OJo tri-sodium citrate were used, then lower levels in plasma may be a simple artifact of the dilution effect (l:9 v/v). We used solid EDTA as an anti-coagulant in an attempt to avoid this issue. We have presumed that our finding of lower concentrations in serum was due to consumption of vWFAg as part of the coagulation system. This may be due in part to et al. '6 Values are median concentrations in this study and references 13 and 15, and mean concentrations in references 14 and 16. "70 = per cent of a normal pool. the function of vWFAg as a platelet aggregant, as some vWFAg domains bind platelet membrane constituents GpIa and GpIIb/IIIa. IO , 17 Our data from patients with GCA and polymyalgia rheumatica (PMR) support previous findings (Table 4 ). Broadly speaking, the same pattern is found by all groups, i.e., raised concentrations relative to controls, in PMR (at least P<O'05) and GCA (generally P<O'OOI), with concentrations higher in GCA relative to PMR (P<O·Ol). An exception is Persellin et al. 15 who failed to find raised levels in patients with PMR. The close agreement of the data is notable in view of its international composition and the variety of the methods used: ELISA, 13 immuno laser nephelometric," electroimmunoassay" and immunoelectrophoresis." Our finding of high concentrations in Sjogren's syndrome are similar to those of Federici et al. 16 (our serum median 222 IU/dL, n = 23; their plasma mean 229070, n = 12).
